12月28日,中国医药行业的两家龙头企业,恒瑞医药与翰森制药同步公告达成合作。根据协议,恒瑞医药将旗下处于Ⅲ期临床阶段的在研药物SHR6508在中国大陆的独家开发、生产和商业化权利授予翰森制药。与此同时,恒瑞的子公司成都盛迪医药与翰森的子公司江苏豪森药业签署了另一份协议,委托后者为已上市的帕立骨化醇软胶囊提供商业化服务。图源:官方公告这笔交易更凭借管线授权搭配商业化服务的组合模式、关联方交易的特殊...
Source Link12月28日,中国医药行业的两家龙头企业,恒瑞医药与翰森制药同步公告达成合作。根据协议,恒瑞医药将旗下处于Ⅲ期临床阶段的在研药物SHR6508在中国大陆的独家开发、生产和商业化权利授予翰森制药。与此同时,恒瑞的子公司成都盛迪医药与翰森的子公司江苏豪森药业签署了另一份协议,委托后者为已上市的帕立骨化醇软胶囊提供商业化服务。图源:官方公告这笔交易更凭借管线授权搭配商业化服务的组合模式、关联方交易的特殊...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.